Erlotinib: Optimizing therapy with predictors of response?

Clinical Cancer Research

Volumn 12, Issue 10, 2006, Pages 2961-2963

  Goodin, Susan ^a,b  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CARBOPLATIN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; PACLITAXEL; RETINOID DERIVATIVE; STEROID;

CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONJUNCTIVITIS; CORNEA ULCER; COUGHING; DIARRHEA; DRUG APPROVAL; DRUG COST; DYSPNEA; FEVER; GASTROINTESTINAL HEMORRHAGE; GENE MUTATION; HUMAN; INTERSTITIAL LUNG DISEASE; KERATITIS; LIVER FUNCTION; LUNG NON SMALL CELL CANCER; MACULOPAPULAR RASH; METASTASIS; PANCREAS CANCER; PREDICTION; PRIORITY JOURNAL; PUSTULE; REVIEW; SIDE EFFECT; SMOKING; TREATMENT RESPONSE;

BIOLOGICAL MARKERS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; ENDPOINT DETERMINATION; FORECASTING; GENE AMPLIFICATION; HUMANS; LUNG NEOPLASMS; PROGNOSIS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 33744822445     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0426     Document Type: Review

References (26)

1. Ciardiello R, Tortora G. Anti-epidermal growth factor receptor drugs in cancer therapy. Expert Opin Investig Drugs 2002;11:755-68.
2. Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001; 19:3267-79.
3. Perez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004;22:3238-47.
4. Miller VA, Herbst RS, Prager D, et al. Long survival of never smoking non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib HCl (OSI-774) and chemotherapy: sub-group analysis of TRIBUTE [abstract 7022]. J Clin Oncol 2004;22: 7061a.
5. Patel JD, Miller VA, Kris MG, et al. Encouraging activity and durable responses demonstrated by the EGFR tyrosine kinase inhibitor erlotinib (Tarceva™, OSI-774) in patients with advanced bronchiolalveolar (BAC) cell carcinoma. Lung Cancer 2003;41:556-1.
6. Shepherd FA, Pereira PR, Ciulenau T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32.
7. Gatzemeier U, Pluzanska A, Szczesna A, et al. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC) [abstract 7010]. J Clin Oncol 2004;22:619s.
8. Herbst RS, Prager D, Herman R, et al. TRIBUTE- A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small cell lung cancer. J Clin Oncol 2005;23:5892-9.
9. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT1 J Clin Oncol 2004;22:777-84.
10. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004;22:785-94.
11. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG] [abstract 1]. J Clin Oncol 2005;23:15.
12. Tsao M-S, Sakurada A, Cutz J-C, et al. Erlotinib in lung cancer: molecular and clinical predictors of outcome. N Engl J Med 2005;353:133-44.
13. Shigematsu H, Gazdar AR. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 2006;118:257-62.
14. Pao W, Miller VA. Epidermal growth factor receptor mutations, small molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 2005;23:2556-68.
15. Shigematsu H, Lin L, Takahashi T et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-46.
16. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 2004;350: 2129-39.
17. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
18. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005;23:5900-9.
19. Bell DW, Lynch TJ, Haserlat SM, et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 2005;23:8081-92.
20. Genzyme Genetics Test Menu [accessed 11/21/ 2005]. Available from: http://www.genzymegenetics. com/testmenu/tests/cancer/gene_p_testmenu_can_ test_EGFR.asp?tests=%2Fcancer%2Fgene_p_test menu_can_test_EGFR. asp&search_only_pre=ON& search_only_cancer=ON.
21. Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 2005;23:5235-46.
22. Amador ML, Oppenheimer D, Perea S, et al. An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res 2004;64:9139-43.
23. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005;2:e17.
24. Kris MG, Sandler VA, Miller MF. EGFR and KRAS mutations in patients with bronchioalveolar carcinoma treated with erlotinib in a phase II multicenter trial [abstract 7029]. J Clin Oncol 2005; 23:627.
25. Kobayashi S, Boggon TJ, Dayaram T et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786-92.
26. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:1-11.